Just over a year after going public, Turnstone Biologics is axing staff, adjusting its leadership team and changing its ...

A small venture capital firm that backs up-and-coming scientists plans to raise a $35 million second fund, three years after ...

Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief ...

The phar­ma in­dus­try’s DC-based lob­by­ing group urged the fed­er­al gov­ern­ment on Fri­day to get on board with ...

The FDA has approved Roche’s inavolisib plus Pfizer's Ibrance and fulvestrant in a subtype of breast cancer over a month ...

Sanofi is ending a Phase 2 clinical trial that's testing a drug from Denali for multiple sclerosis, ending the development ...

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

Sen. Elizabeth Warren (D-MA) has put the spotlight on Novo Holdings’ acquisition of Catalent, expressing concerns that the ...

Seven young boys treated with bluebird bio’s gene therapy for a rare neurological disease have been diagnosed with blood ...

Eli Lilly is returning to KeyBioscience, a nimble Swiss biotech, seven years after originally linking arms with the startup ...

Immatics said its PRAME-targeted T cell therapy shrank tumors by at least 30% in just over half of melanoma patients in an ...

The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from ...